Fennec Pharmaceuticals (TSE:FRX) Stock Price Down 1.9%

Fennec Pharmaceuticals Inc (TSE:FRX) was down 1.9% during trading on Thursday . The stock traded as low as C$6.05 and last traded at C$6.05, approximately 100 shares changed hands during mid-day trading. A decline of 93% from the average daily volume of 1,468 shares. The stock had previously closed at C$6.17.

The company has a 50-day simple moving average of C$5.96 and a 200 day simple moving average of C$5.79. The company has a market capitalization of $116.39 million and a P/E ratio of -9.04.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported C($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.19) by C($0.13).

About Fennec Pharmaceuticals (TSE:FRX)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

See Also: Overbought

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.